Business
Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model
Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"LOS ANGELES, CA / ACCESSWIRE / January 3, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ (\"Sunshine\") diabetes test strip, the new internationally launched GenSure!™ (\"Feather\") diabetes test strip, and the clinical trial ready GenChoice!™ (\"Ladybug\") diabetes test strip, as well as three other unique test strips and meters in development, including our panacea strip and meter system the highly innovative GenPrecis!™ and its first collateral asset, our GenAccord!™ multiple-egress test strip. Today, DECN previews its plans and expected outcomes for 2018.J&J LitigationDECN has been locked in confrontational patent litigation with two divisions of Johnson & Johnson (JNJ), almost continuously, since September 2011. The company was victorious as a Defendant in the first three suits and received a payout at their conclusion. The current lawsuit positions two divisions of DECN as plaintiffs having filed suit against J&J for infringement of the company's patented test strip technology. As anticipated, J&J has employed the identical deceptive tactics and delaying strategies they embraced during the prior litigations. They failed to affect the final outcome in the past and it is expected that they will fail once again. The company's legal positions are strong and are supported by the rulings made by higher courts in the first three cases. If necessary, the company is fully prepared, both legally and financially, to litigate until J&J has exhausted their final appeal. However, the company believes that the strength of its position will ultimately drive a negotiated settlement.Keith Berman, CEO of Decision Diagnostics Corp., commented, \"J&J, through their superior resources and \"scorched earth\" legal strategy, has exacted heavy tolls on our business operations. However, through this adversity, the company has discovered its footing as a legitimate competitor in a highly regulated and heavily litigious environment. We are now fortified and fully prepared to successfully engage as we introduce new products and continue to expand our base of business.\"New Product Introductions2018 is expecte...